99 Markers of neurodegeneration in subjective cognitive decline 13. Ottoy J, Niemantsverdriet E, Verhaeghe J, De Roeck E, Struyfs H, Somers C, et al. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging. Neuroimage Clin. 2019;22:101771. 14. Yu JT, Li JQ, Suckling J, Feng L, Pan A, Wang YJ, et al. Frequency and longitudinal clinical outcomes of Alzheimer’s AT(N) biomarker profiles: A longitudinal study. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2019;15(9):1208-17. 15. Guo Y, Li HQ, Tan L, Chen SD, Yang YX, Ma YH, et al. Discordant Alzheimer’s neurodegenerative biomarkers and their clinical outcomes. Annals of clinical and translational neurology. 2020;7(10):1996-2009. 16. van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer’s disease : JAD. 2018;62(3):1091-111. 17. Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, et al. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers Res Ther. 2018;10(1):76. 18. Verhage F, Van Der Werff JJ. [AN ANALYSIS OF VARIANCE BASED ON THE GRONINGER INTELLIGENCE TEST SCORES]. Nederlands tijdschrift voor de psychologie en haar grensgebieden. 1964;19:497-509. 19. Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens P, Muller M, et al. MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Frontiers in Aging Neuroscience. 2017;9:117. 20. Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology. 2020;95(1):e46-e58. 21. Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: International standardization to optimize biomarker development. Clinical Biochemistry. 2014;47(4):288-92. 22. Duits FH, Prins ND, Lemstra AW, Pijnenburg YA, Bouwman FH, Teunissen CE, et al. Diagnostic impact of CSF biomarkers for Alzheimer’s disease in a tertiary memory clinic. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2015;11(5):523-32. 23. Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, van Berckel BNM, et al. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-beta 1-42 Analysis Results. Clinical chemistry. 2018;64(3):576-85. 24. de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, et al. Alzheimer’s biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer’s & dementia (Amsterdam, Netherlands). 2017;6:143-51. 25. Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, et al. Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9(1):2. 26. Ossenkoppele R, Zwan MD, Tolboom N, van Assema DME, Adriaanse SF, Kloet RW, et al. Amyloid burden and metabolic function in early-onset Alzheimer’s disease: parietal lobe involvement. Brain : a journal of neurology. 2012;135(7):2115-25. 4
RkJQdWJsaXNoZXIy MjY0ODMw